CELLINK showcases bioprinting progress at the Collaborative Partnership Conference
Bioprinting company CELLINK is continually striving to advance the possibilities of additive manufacturing in the medical, and specifically bioprinting, field. To highlight its efforts, the company recently hosted a Collaborative Partnership Conference on May 10 in Milan, Italy. The event was the perfect opportunity to showcase the technological solutions offered by the company and, above all, the current use cases for them.
The event was held at the San Raffaele Hospital and brought together various Italian and foreign companies that are using CELLINK’s bioprinters to develop highly innovative research projects. Arguably the most relevant were the case studies shown by the San Raffaele Scientific Institute and by the University of Pavia, the most 3D printing-oriented university in Italy known for opening 3D4Med, the first Clinical 3D Printing Laboratory in Italy and one of the few international companies of its kind.
The CELLINK Collaborative Partnership Conference provided a comprehensive overview of the applicability of bioprinting in critical fields such as research for autoimmune diseases treatments and regenerative medicine, with a lot of examples that demonstrate how CELLINK’s systems can help experts to obtain concrete results and more reliability. Most importantly, this general overview of concrete use cases proves that the company’s 3D bioprinting is an important tool for medical and scientific research.
In the end, the Collaborative Partnership Conference was an opportunity to see the Lumen X bioprinter in action. The machine, released in March 2019, was developed for the vascular sector in partnership with Volumetric. Thanks to one million light points, it is capable of bioprinting microscopic features down to 200 microns. With this capability, the Lumen X could mark a real turning point for vascular research, assuring the fast production of complex vascular structures.
